Table 1 Functional outcomes of eyes with treatment naïve neovascular age-related macular degeneration
Baseline BCVA, mean ± SD | 0.92 ± 0.50 logMAR (39.0 ± 24.8 ETDRS letters) |
|---|---|
Post-treatment BCVA, mean ± SD | |
At 6 months | 0.74 ± 0.51 logMAR (47.9 ± 25.3 ETDRS letters) |
At 12 months | 0.71 ± 0.50 logMAR (49.3 ± 24.9 ETDRS letters) |
Mean change in BCVA, mean ± SD | |
At 6 months | − 0.17 ± 0.40 logMAR (+ 8.7 ± 20.2 ETDRS letters) |
At 12 months | − 0.20 ± 0.40 logMAR (+ 10.1 ± 20.1 ETDRS letters) |
Eyes gaining ≥ 0.3 logMAR units (15 ETDRS letters, ~ 3 Snellen lines), n (%) | |
At 6 months | 67 (31%) |
At 12 months | 72 (34%) |
Eyes with ≤ 0.3 logMAR vision (≥ 70 ETDRS letters, ~ Snellen VA ≥ 20/40), n (%) | |
At 6 months | 39 (18%) |
At 12 months | 47 (22%) |